Tally Health is under new ownership.
The biotechnology platform, which performs epigenetic age testing for consumers and tailors product and lifestyle recommendations for them, has been acquired by Infinite Epigenetics in a deal of undisclosed size.
Infinite Epigenetics, and its subsidiary TruDiagnostic, will continue under the leadership of chief executive officer Dr. Matthew Dawson, while Tally’s CEO Melanie Goldey will stay on as well.
“Their business is predominantly [business-to-business]. They work with research organizations, academia, payers and providers, and they do have a small consumer business as well. But Tally is really meant to augment what they have built,” Goldey said. “We’re going to continue operating Tally from within Infinite Epigenetics, so our customers are not going to see any disruption or anything. We’re going to continue to do what we do, but we get to leverage all of the really cool data and science that Infinite and TruDiagnostic have.”
Tally launched in 2023, and draws on a DNA methylation dataset of some 8,000 initial participants to evaluate consumers’ epigenetic ages based on a cheek swab. “It was really trained on a diverse cohort of people, which I think matters when you’re talking about creating a consumer tool for a lot of people,” Goldey said. After the epigenetic test, “There are two buckets of intervention.”
The first is personalized health and wellness recommendations, and the latter are the company’s six supplements they’ve developed. “They’re categorized in a way that hopefully the consumer can look at those different formulations and see a problem that they might have. We have a sleep supplement, for example, and we have one for metabolic health, which helps maintain your blood glucose levels and give you a boost of energy. Another one that’s really popular is our brain health supplement,” she said.
Tally will be able to leverage its parent company’s data and labs for research and development. Goldey is still bullish on the business from a demographic standpoint, too. At launch, it attracted biohackers who skewed male, although most of the growth has come from women.
“I like to call them the chief medical officers of the home, because they’re making decisions for themselves, their kids, maybe their aging parents,” Goldey said. “The age has widened to 30 to 60. That’s been great to see, too. I think younger people are becoming extremely sophisticated about taking advantage of how to live longer and healthier.”
She posited that the gap between lifespan and healthspan, which is considerably wider in the U.S. than other geographies, also points to a consumer need for the product. “A big problem in the U.S., and this sort of speaks to the mission of epigenetics and why it’s going to become a larger field for health care, a lot of consumers just are not aware that these tools or this science exists,” she said. “For us, it’s about how we take that consumer brand and channel, and work with other b-to-b constituents. Life insurance, health insurance, they should be looking at epigenetics and not just your date of birth. That’s the future of where this is going.”
